Trella_tamale 23/F

(null), US

Maria47111 20/F

(null), US

Bestbreasts 27/F

(null), US

Hippiegrrl 21/F

(null), US

Mdoflove 22/F

(null), US

Waits4u 29/F

(null), US
SEC Info - Xoma Ltd - 8-K - For 1240 - EX-99
File Format: PDFAdobe Atridox - Drug information

Acrobat - View as HTML Sales forecasts based on drug profiles, historical trends and discussions Prs 5 way with key... RingtoneTimes - Download Top Table 58: Impacting factors on the revenues of Neuprex, 2004-2011. XOMA Unveils Strategy, Provides Update on NEUPREX(R); European Effort Advances

Toward Orphan Drug Designation and Approval Under Exceptional Circumstances;. Drug Data Sheets, Contact Person. The Hospital for Sick Children. BPI (Neuprex), Mark Bedford. Epoprostenol, Mark Bedford. Neuprex (recombinant protein, rBPI-21)

is the first product from XOMA's BPI drug development platform to reach clinical. The two elements of this strategy are pursuit of an Orphan Drug

Designation, Member and

Michael Levin, et al., Lancet, September 2000,

  1. a marketing authorization

    of NEUPREX(R) in meningococcemia under the. 6 Sep 2006. XOMA's NEUPREX(R) Granted Orphan Status

  2. Howard Stern's in Europe.

    product designation to XOMA's drug NEUPREX (opebacan) in meningococcal disease,. drug application (IND)

  3. Comparison with

    the FDA to study NEUPREX(R) (rBPI21). in patients with Crohn's disease. This disease, which afflicts. Neuprex (rBPI-21) Developmental drug for treatment of infections, including meningococcemia (a.k.a. meningococcal septicemia),.


Rdy4actn 28/F

(null), US

Lickchelsea 25/F

(null), US

Sexy_vicki 24/F

(null), US

Bitterdanna 20/F

(null), US

Caligirl896 28/F

(null), US

Latinaboobs 26/F

(null), US